The blinded six-month interim analysis of the PRECISE-AD phase I-B trial showed PMN310 has a strong safety profile with no ARIA-E and favorable biomarker trends, including declines in p-tau217 and MTBR-tau243. These results suggest target engagement and potential disease modification, pending confi…
The 6-month blinded interim analysis of a Phase 1b Alzheimer's trial showed no ARIA-E, a low total ARIA rate, and favorable safety across all genotypes. Both plasma pTau217 and CSF MTBR-tau243 biomarkers declined, suggesting early target engagement and potential disease modification. Topline 12-mon…
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteersRepresents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trialCompany on track to present six-month…
